Fast track approval by MHRA

For acute severe pain in children and adolescents (from 2 to 15 years).

Developed in collaboration with Wockhardt, launched and marketed by Wockhardt in 2015.

Therakind devised regulatory strategy, designed and managed two clinical trials spanning over 10 sites, and a post-authorisation trial spanning 20 sites.